Please login to the form below

Not currently logged in
Email:
Password:

Merck/ Parexel biosimilar alliance

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates.

The agreement will see Parexel, a contract research organisation (CRO) with a focus on the biopharma industry, provide Merck  with access to global clinical development services for designated biosimilar candidates. The biosimilar candidates span several therapy areas.

A dedicated unit of Merck BioVentures,  the division of Merck focused on the development of biosimilars, will also be established within Parexel.

Financial details of the deal were not disclosed.

"Through this agreement, Merck BioVentures has secured broad strategic access to Parexel's proven biosimilar clinical development experience," said Michael Kamarck, president , Merck BioVentures. "This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace."

Josef von Rickenbach, chairman and CEO of Parexel, was also positive about the agreement: "We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide."

13th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics